Somatostatin Receptor Inhibitor

Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.

Sstr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR1 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SRA880 (free base) is a compound with antidepressant-modulating effects. It is a somatostatin-1 autoreceptor antagonist that can synergize with imipramine to produce antidepressant-like effects and affect BDNF mRNA expression and phosphorylation of related proteins.

Sstr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Des-threoninol-octreotide (Compound 13) is a Somatostatin analog. Des-threoninol-octreotide inhibits cloned somatostatin receptors with IC₅₀ values of 13.62 nM, 10.63 nM, 10.95 nM for mSSTR2b, rSSTR5 and hSSTR5, respectively.

SSTR3 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172).

Sstr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64).

MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265).

SSTR5 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR4 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.